Pharmacosmos today announces the establishment of a subsidiary in Beijing, China and that it has reacquired all commercialisation rights for the Pharmacosmos’ portfolio of intravenous iron products in China.
The Chinese market of intravenous iron for the treatment of iron deficiency (ID) and iron deficiency anaemia (IDA) is one of the largest in the world. Nonetheless, IDA remains prevalent and there is a substantial unmet need for new treatment options. The new generation of innovative IV irons has yet to be made available to patients in the Chinese health care system and is expected to expand the use of IV irons across multiple therapeutic areas.
IDA is a frequent condition for patients across various therapeutic areas and the general prevalence of anaemia in the Chinese population is approx. 20%
‘We are proud to be able to significantly contribute to the treatment of the many patients in China suffering from iron deficiency and iron deficiency anaemia. By establishing a subsidiary in China, we are now present with a passionate organisation dedicated to the treatment of this debilitating condition’ says Lars Christensen, MD, President and CEO of Pharmacosmos A/S.
The establishment of Pharmacosmos in China follows the establishment of Pharmacosmos Therapeutics in the US in 2020.
'We are in the fortunate position that we now have the experiences and capabilities of establishing subsidiaries in the world’s largest pharma markets. Markets in which the need for our value proposition is increasing significantly’, says Lars Christensen.
Pharmacosmos in China is headed by Kathy Liu, MD, who has more than 17 years of experience from the pharmaceutical industry including senior positions with Lundbeck, Pfizer, and Janssen.
‘I’m very excited about establishing Pharmacosmos in China. Our new organisation is commercially very skilled and experienced, and I firmly believe that we will soon become a leading player in the treatment of iron deficiency and iron deficiency anaemia in China’, says the Managing Director of Pharmacosmos in China, Kathy Liu.
Tobias S. Christensen, Vice President, Corporate Development and Strategy
+45 5948 5959, email@example.com
Pharmacosmos Group, headquartered in Holbaek, Denmark, and founded in 1965, is a highly specialised company focused on carbohydrate chemistry and a global leader in the development of innovative treatments for patients suffering from iron deficiency and iron deficiency anaemia. With companies in the UK, Nordics, Germany, the USA and recently also in China, and through partners, Pharmacosmos markets its products across the world. With a strong and ongoing commitment to R&D, Pharmacosmos is able to leverage a unique carbohydrate production platform along with deep expertise in the synthesis of iron-carbohydrate complexes.
You are now leaving Pharmacosmos.com. The website you are about to visit is is a Pharmacosmos subsidary. Do you want to proceed?